Technical Analysis for HEM - Hemostemix Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.040 | -11.11% | -0.005 |
HEM closed down 11.11 percent on Friday, July 26, 2024, on 27 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Aug 12
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -11.11% | |
| Narrow Range Bar | Range Contraction | -11.11% | |
| Stochastic Reached Oversold | Weakness | -11.11% | |
| Wide Bands | Range Expansion | -11.11% | |
| Oversold Stochastic | Weakness | -11.11% | |
| MACD Bearish Centerline Cross | Bearish | -11.11% | |
| Wide Bands | Range Expansion | -11.11% | |
| Gapped Down | Weakness | -11.11% |
| Alert | Time |
|---|---|
| 2x Volume Pace | 5 days ago |
| Down 5% | 5 days ago |
| Down 3% | 5 days ago |
| Down 2% | 5 days ago |
| Down 1% | 5 days ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2024-08-12
Hemostemix Inc is a Canada-based clinical-stage biotechnology company. The Company's principal business is to develop, manufacture and commercialize blood-derived cell therapies for medical conditions, including critical limb ischemia (CLI). The Company's clinical-stage candidate, ACP-01, is an autologous cell therapy for the treatment of CLI. ACP-01 is in a Phase II clinical trial in Canada, South Africa and the United States. The Company also focuses on developing other cell products, such as bone cell precursors (BCPs), myocardial cell precursors (MCPs) and neural cell precursors (NCPs). It operates in Canada and Israel. The Company has approximately 2,200 square foot research and manufacturing facility in Ness Ziona, Israel. Hemostemix Limited is the subsidiary of the Company.
Sector: Healthcare
Industry: Biotechnology
Keywords: Manufacturing Nature Clinic Biotechnology Biology Therapy Clinical Trial Bone Hypertension Stem Cells Cell Biology Cell Products Cell Therapy Manufacturing Facility
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Manufacturing Nature Clinic Biotechnology Biology Therapy Clinical Trial Bone Hypertension Stem Cells Cell Biology Cell Products Cell Therapy Manufacturing Facility
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.175 |
| 52 Week Low | 0.035 |
| Average Volume | 86,175 |
| 200-Day Moving Average | 0.074 |
| 50-Day Moving Average | 0.048 |
| 20-Day Moving Average | 0.049 |
| 10-Day Moving Average | 0.048 |
| Average True Range | 0.007 |
| RSI (14) | 43.82 |
| ADX | 14.97 |
| +DI | 33.108 |
| -DI | 32.914 |
| Chandelier Exit (Long, 3 ATRs) | 0.048 |
| Chandelier Exit (Short, 3 ATRs) | 0.057 |
| Upper Bollinger Bands | 0.064 |
| Lower Bollinger Band | 0.034 |
| Percent B (%b) | 0.21 |
| BandWidth | 62.857 |
| MACD Line | -0.001 |
| MACD Signal Line | 0.000 |
| MACD Histogram | -0.0013 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.048 | ||||
| Resistance 3 (R3) | 0.048 | 0.047 | 0.046 | ||
| Resistance 2 (R2) | 0.047 | 0.045 | 0.046 | 0.046 | |
| Resistance 1 (R1) | 0.043 | 0.044 | 0.043 | 0.043 | 0.045 |
| Pivot Point | 0.042 | 0.042 | 0.041 | 0.041 | 0.042 |
| Support 1 (S1) | 0.038 | 0.040 | 0.038 | 0.038 | 0.035 |
| Support 2 (S2) | 0.037 | 0.039 | 0.036 | 0.034 | |
| Support 3 (S3) | 0.033 | 0.037 | 0.034 | ||
| Support 4 (S4) | 0.033 |
